Drug | Total (N = 1,324) | KABS (N = 916) | ACB (N = 975) | ||||
---|---|---|---|---|---|---|---|
Number of patients (%) | Average DDD per patient per year | score | Contribution to high exposure (%) | score | Contribution to high exposure (%) | ||
chlorpheniraminea, b | 1,297 | (98.0) | 17 | 3 | 5.8 | 3 | 5.2 |
tramadola | 1,262 | (95.3) | 9.2 | 2 | 2.3 | 0 | 0 |
cimetidinea, b | 1,260 | (95.2) | 46.7 | 2 | 11.6 | 1 | 4.0 |
diazepama, b | 1,198 | (90.5)) | 34.8 | 1 | 4.2 | 1 | 3.4 |
ranitidinea, b | 1,150 | (86.9) | 28.6 | 1 | 3.1 | 1 | 3.0 |
hydrochlorothiazideb | 974 | (73.6) | 80.2 | 0 | 0 | 1 | 10.1 |
alprazolama, b | 921 | (69.6) | 32.5 | 1 | 4.1 | 1 | 3.2 |
dimenhydrinatea, b | 869 | (65.6) | 33.3 | 3 | 11.3 | 3 | 11.7 |
amitriptylinea, b | 727 | (54.9) | 10.9 | 3 | 3.8 | 3 | 3.4 |
theophyllinea, b | 664 | (50.2) | 13.8 | 1 | 1.5 | 1 | 1.5 |
furosemidea, b | 606 | (45.8) | 39.5 | 1 | 4.3 | 1 | 5.0 |
atenololb | 549 | (41.5) | 33 | 0 | 0 | 1 | 4.3 |
lorazepama | 515 | (38.9) | 11.9 | 1 | 1.5 | 0 | 0 |
nifedipineb | 459 | (34.7) | 38 | 0 | 0 | 1 | 5.2 |
triazolama | 454 | (34.3) | 15.8 | 1 | 2.1 | 0 | 0 |
octylonium bromidea | 451 | (34.1) | 4.5 | 3 | 1.8 | 0 | 0 |
tolterodinea, b | 355 | (26.8) | 7.9 | 3 | 2.7 | 3 | 2.8 |
propiverinea, b | 342 | (25.8) | 6.3 | 3 | 2.2 | 3 | 2.2 |
isosorbideb | 290 | (21.9) | 40.2 | 0 | 0 | 1 | 5.4 |
doxazosinb | 263 | (19.9) | 18.1 | 0 | 0 | 1 | 2.4 |
digoxinb | 215 | (16.2) | 13.3 | 1 | 1.2 | 1 | 1.7 |
paroxetinea, b | 209 | (15.8) | 9.3 | 2 | 2.1 | 3 | 3.5 |
quinupraminea | 188 | (14.2) | 5.1 | 3 | 2.2 | 0 | 0 |
solifenacina, b | 174 | (13.1) | 6.1 | 3 | 2.1 | 3 | 2.3 |
levodopa and decarboxylase inhibitora | 166 | (12.5) | 12.6 | 1 | 1.8 | 0 | 0 |
beztropineb | 77 | (5.8) | 3.6 | 3 | 1.4 | 3 | 1.3 |
amantadinea | 76 | (5.7) | 6.3 | 2 | 1.8 | 2 | 1.1 |